secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001558370-21-010404
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics names Harout Semerjian CEO to succeed retiring Rachel King; Q2 cash $118.9M
--------------------------------------------------------------------------------

- CEO Rachel King retires effective Aug 6, 2021; remains on board and as consultant. Harout Semerjian appointed CEO effective Aug 6.
- New CEO receives $595K salary, $200K sign-on bonus, target bonus 55%, and stock options for ~1.65M shares with milestone-based vesting.
- As of June 30, 2021, cash and equivalents $118.9M (down from $137.0M at Dec 31, 2020); Q2 R&D $10.2M, G&A $4.2M.
- Enrollment in Phase 3 relapsed/refractory AML trial and NCI Phase 2/3 trial expected to complete by year-end 2021.
- Compensation Committee increased Inducement Plan shares from 500K to 2M; grants to new CEO from this plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/0001558370-21-010404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/glyc-20210730x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-010404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer